[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hand-eczema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hand-eczema":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,36,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100643807","ppdtm-corevitastm-chronic-hand-eczema-che-drug-safety-and-effectiveness-registry-100643807",false,"NCT07598058","PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry","Inclusion Criteria:\n\n* To be eligible to participate in this registry, an individual must meet all of the following criteria:\n\n  1. Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time of enrollment and initiating an eligible medication.\n  2. Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment\n  3. Is willing and able to consent to participation in the registry\n  4. Is willing and able to complete registry-related forms electronically via personal devices.\n  5. Is willing and able to provide the information (first name, last name, email address, language and primary time zone) required to create an account to allow you to complete registry forms via a personal device;\n  6. Is willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip or postal code and email address or phone number at a minimum) if required based on registry location and applicable laws and regulations.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the registry:\n\n1\\) Is participating or planning to participate in a blinded clinical trial for a CHE drug","ALL","18 Years",{"count":18,"type":19},2000,"ESTIMATED","OBSERVATIONAL","The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method",[23],"Chronic Hand Eczema","NOT_YET_RECRUITING","2026-06-05",{"date":27,"type":28},"2026-06-09","ACTUAL",{"date":30,"type":19},"2026-05-29",{"date":32,"type":19},"2099-12-31",{"name":34,"class":35},"CorEvitas","NETWORK",{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":15,"minAge":16,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100441300","characterization-of-chronic-hand-eczema-100441300","NCT05026554","Characterization of Chronic Hand Eczema","Pathophysiological Characterization of Chronic Hand Eczema Subtypes and Atopic Dermatitis With Noninvasive Molecular and Imaging Techniques in Subjects With Moderate to Severe Chronic Hand Eczema, Subjects With Atopic Dermatitis, and Healthy Volunteers","Inclusion Criteria:\n\nAll subjects:\n\n1. Male or female subjects aged 18 to 65 years, inclusive, at the time of consent.\n2. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n3. Subject must be willing to comply with all study procedures and must be available for the duration of the study.\n\n   CHE subjects only:\n4. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n5. Subject has moderate to severe CHE as defined by an IGA score of ≥3 at Screening and Day 1.\n6. Subject has CHE covering ≥0.25% of BSA on palmar surface of hands at Screening and Day 1.\n7. Subjects has CHE that can be categorized in one of the following CHE subtypes at Day 1:\n\n   * Atopic hand eczema (without wet-work or excessive contact with irritants)\n   * Irritant contact hand eczema without atopic disease\n   * Hyperkeratotic hand eczema without atopic disease\n   * Vesicular hand dermatitis without atopic disease\n   * Allergic contact hand eczema without atopic disease\n   * Idiopathic hand eczema without wet-work, excessive contact with irritants, atopic disease, hyperkeratotic morphology, allergic contact hand eczema and vesicular hand eczema.\n\n   Subjects with only AD:\n8. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.\n9. Subject has at least a 6-month history of AD and had no significant flares in AD for at least 4 weeks before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n10. Subject has moderate to severe AD as defined by a vIGA-AD score of ≥3 at Screening and Day 1.\n11. Subject has AD covering ≥0.5% of BSA at Screening and Day 1.\n12. Subject has an AD lesion covering ≥0.25% of BSA on the forearm at Screening and Day 1.Healthy Volunteers only:\n13. Subject is in good general health, according to the investigator's judgment based on medical history and physical examination.\n\nExclusion Criteria:\n\nAll subjects:\n\n1. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.\n2. Subject has used systemic antibiotics within 2 weeks prior to Day 1.\n3. Subject has used topical antibiotics within 1 week prior to Day 1.\n4. Subject has used topical products containing urea or salicylic acid within 1 week prior to Day 1.\n5. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.\n6. Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.\n7. Subject has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1. Use of sunscreen products are recommended when exposure cannot be avoided.\n8. Subject is a female who is pregnant or who is planning to become pregnant during the study.\n\n   CHE subjects only:\n9. Subject has clinically infected chronic hand eczema on hands and\u002For wrists.\n10. Subject with suspected or proven hand eczema protein contact dermatitis.\n11. Subject has used doxepin within 1 week prior to Day 1.\n12. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.\n13. Subject has used any topical medicated treatment that could affect CHE within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, topical retinoids, crisaborole, calcineurin inhibitors, tars, antimicrobials, medical devices, and bleach baths.\n14. Subject has used alitretinoin, isotretinoin, acitretin or other systemic retinoids within 4 weeks before Day 1, or has not completely recovered from its side effects.\n15. Subject has used systemic treatments (other than biologics) that could have an impact on CHE less than 4 weeks prior to Day 1 (eg, calcineurin inhibitors, methotrexate, cyclosporin, hydroxycarbamide \\[hydroxyurea\\], azathioprine), or systemic steroids (including oral or injectable corticosteroids).\n\n    Note: Intranasal corticosteroids, eye or ear drops containing corticosteroids, and inhaled corticosteroids for stable medical conditions are allowed.\n16. Subject has used dupilumab within 12 weeks prior to Day 1.\n17. Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.\n18. Subject has had psoralen-UV-A (PUVA) treatment within 4 weeks prior to Day 1.\n\n    Subjects with only AD:\n19. Subject has clinically infected AD.\n20. Subject has AD lesion on hand and\u002For feet at screening or Day 1.\n21. Subject has received an intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Day 1.\n22. Subject has used doxepin within 1 week prior to Day 1.\n23. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.\n24. Subject has used any topical, medicated treatment that could affect AD within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole, calcineurin inhibitors, ruxolitinib, tars, antimicrobials, medical devices, and bleach baths.\n25. Subject has used systemic treatments (other than biologics) that could affect AD less than 4 weeks prior to Day 1, including, but not limited to, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids, baricitinib, upadacitinib, and abrocitinib.\n26. Subject has used dupilumab within 12 weeks prior to Day 1.\n27. Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.\n28. Subject has had PUVA treatment within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are allowed.\n29. Subject has used tralokinumab within 12 weeks prior to Day 1.\n\n    Healthy Volunteers only:\n30. Subject has history of atopic dermatitis, allergic rhinitis, or asthma.",true,"65 Years",{"count":46,"type":19},270,"Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.",[23,49],"Atopic Dermatitis","RECRUITING","2026-04-06",{"date":53,"type":28},"2026-04-09",{"date":55,"type":28},"2021-06-30",{"date":57,"type":19},"2027-09-30",{"name":59,"class":60},"Dr. Robert Bissonnette","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":43,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":61},"100515705","collection-of-samples-from-subjects-with-various-skin-conditions-and-healthy-volunteers-100515705","NCT05994976","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers for Molecular Characterization of Inflammatory Skin Diseases","Inclusion Criteria:\n\nAll subjects:\n\n1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n2. Subject must be willing to comply with all study procedures and must be available for the duration of the study.\n\n   Healthy volunteers:\n3. Male or female subject aged 18 years or older, at the time of consent.\n4. Subject is in good general health, according to the investigator's judgment.\n\n   Subjects with Acne:\n5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.\n\n   Subjects with AD:\n6. Male or female subject aged 18 years or older, at the time of consent.\n7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.\n\n   Subjects with CHE:\n8. Male or female subject aged 18 years or older, at the time of consent.\n9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n\n   Subjects with HS:\n10. Male or female subject aged 18 years or older, at the time of consent.\n11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and\u002For review of the medical history.\n\n    Subjects with PPP:\n12. Male or female subject aged 18 years or older at the time of consent.\n13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and\u002For soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject).\n\n    Subjects with psoriasis:\n14. Male or female subject aged 18 years or older, at the time of consent.\n\nExclusion Criteria:\n\nAll subjects:\n\n1. Subject is a female who is pregnant or who is planning to become pregnant during the study.\n2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.",{"count":70,"type":19},500,"The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.",[73,49,23,74,75,76],"Acne","Hidradenitis Suppurativa","Plaque Psoriasis","Palmoplantar Pustulosis","2026-03-25",{"date":79,"type":28},"2026-03-30",{"date":81,"type":28},"2023-10-17",{"date":83,"type":19},"2028-08",{"name":85,"class":60},"Innovaderm Research Inc."]